uridine has been researched along with decitabine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 8 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| Bernheim, J; Buyssens, N; Cortvrindt, R; Roobol, K | 1 |
| DeSimone, J; Hall, L; Heller, P; Molokie, RE; Zwiers, D | 1 |
| Engelbrecher, A; Häuser, R; Titz, B; Uetz, P | 1 |
| Banerjee, D; Bertino, JR; Humeniuk, R; Mishra, PJ | 1 |
| Hosokawa, M; Iwakawa, S; Ueda, K | 1 |
| Amrein, PC; Azab, M; DeZern, AE; Faderl, S; Garcia-Manero, G; Harb, W; Kantarjian, H; Lowder, J; Michaelis, LC; Odenike, O; Oganesian, A; Savona, MR; Steensma, DP | 1 |
| Duchmann, M; Itzykson, R | 1 |
| Azab, M; Brandwein, J; Busque, L; DeZern, AE; Garcia-Manero, G; Griffiths, EA; Kantarjian, H; McCloskey, J; Michaelis, LC; O'Connell, C; Odenike, O; Oganesian, A; Roboz, GJ; Savona, MR; Steensma, DP; Wells, R; Yee, K | 1 |
| Dhillon, S | 1 |
| Azab, M; Griffiths, EA; Oganesian, A; Thota, S | 1 |
| H Wei, A; Kipp, D | 1 |
| Cahill, K; Odenike, O; Patel, AA; Saygin, C | 1 |
| Griffiths, EA | 1 |
| Chen, H; de Claro, RA; Earp, J; Ehrlich, LA; Gehrke, BJ; Kim, N; Kitabi, E; Manning, ML; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Subramaniam, S; Vallejo, J | 1 |
4 review(s) available for uridine and decitabine
| Article | Year |
|---|---|
Clinical update on hypomethylating agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Combinations; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2019 |
Decitabine/Cedazuridine: First Approval.
Topics: Administration, Oral; Adult; Canada; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Combinations; Drug Development; History, 21st Century; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; United States Food and Drug Administration; Uridine | 2020 |
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease Management; Drug Approval; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Treatment Outcome; Uridine | 2021 |
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2021 |
3 trial(s) available for uridine and decitabine
| Article | Year |
|---|---|
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Safety; Treatment Outcome; Uridine | 2019 |
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capsules; Cross-Over Studies; Decitabine; Disease Progression; DNA Methylation; DNA-Cytosine Methylases; Drug Combinations; Drug Monitoring; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Least-Squares Analysis; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Long Interspersed Nucleotide Elements; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Tablets; Uridine | 2020 |
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Topics: Adult; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes; Tablets; Treatment Outcome; Uridine | 2022 |
10 other study(ies) available for uridine and decitabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cells, Cultured; Cytidine; Decitabine; Drug Resistance; Melanoma; Mice; Mutation; Uridine | 1987 |
Tetrahydrouridine, cytidine analogues, and hemoglobin F.
Topics: Agranulocytosis; Animals; Azacitidine; Cytidine Deaminase; Decitabine; Fetal Hemoglobin; Gene Expression Regulation; Globins; Granulocytes; Papio; Tetrahydrouridine; Uridine | 1985 |
The Escherichia coli protein YjjG is a house-cleaning nucleotidase in vivo.
Topics: Azacitidine; Bromodeoxyuridine; Decitabine; Deoxyuridine; DNA Damage; Escherichia coli; Escherichia coli Proteins; Fluorouracil; Models, Biological; Molecular Structure; Mutation; N-Glycosyl Hydrolases; Nucleotidases; Orotic Acid; Substrate Specificity; Thymidine Monophosphate; Uridine | 2007 |
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Order; Humans; Mice; Mice, Nude; Molecular Sequence Data; Nucleoside-Phosphate Kinase; Promoter Regions, Genetic; RNA Stability; Uridine; Xenograft Model Antitumor Assays | 2009 |
Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Colorectal Neoplasms; Decitabine; DNA Methylation; Equilibrative Nucleoside Transporter 1; Gene Expression; HCT116 Cells; Humans; Melanoma-Specific Antigens; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thioinosine; Uridine | 2015 |
Decitabine and Cedazuridine.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Cytidine Deaminase; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Labeling; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Myelodysplastic Syndromes; Uridine | 2020 |
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Approval; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Uridine | 2021 |
Oral hypomethylating agents: beyond convenience in MDS.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Myelodysplastic Syndromes; Quality of Life; Uridine | 2021 |